Compare Boston Scientific Corporation (BSX) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Nasdaq100 ETF — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Nasdaq100 ETF trades at $721.7. The key difference: Nasdaq100 ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | QQQ | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | — |
52-Week High | $108.14 | $746.16 |
52-Week Low | $42.63 | $553.88 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
QQQ, tracking the Nasdaq-100, trades at $711.79, down 1.9% over 24 hours amid a bearish technical signal. The ETF faces mixed sentiment with a 50/50 split in analyst ratings and news highlighting SpaceX's inclusion and competitive pressures from new funds like BlackRock's IQQ. Support sits near $700, with resistance at $717, while oscillators like the RSI remain neutral, suggesting indecision in the short term.
Outlook is cautious due to technical weakness and divided analyst views, though long-term exposure to tech giants offers growth potential. Risks include index concentration, fee competition, and macroeconomic shifts affecting rate-sensitive holdings, requiring careful monitoring of earnings trends from underlying companies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
